Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum: Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Genes & development·2026
Same author

Steatosis shapes prognosis-defining liver metastasis heterogeneity in CRC.

Nature·2026
Same author

A CDCA2-MYC positive feedback loop controls cancer cells survival.

Open biology·2026
Same author

MYC at the tumor-immune interface: mechanisms of immune escape and immunotherapy resistance.

Frontiers in immunology·2026
Same author

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition.

Frontiers in cell and developmental biology·2026
Same author

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jul 23, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Targeting MYC-driven lymphoma: lessons learned and future directions.

Sandra Martínez-Martín1, Marie-Eve Beaulieu1, Laura Soucek1,2,3

  • 1Peptomyc S.L., Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.

Cancer Drug Resistance (Alhambra, Calif.)
|July 17, 2023
PubMed
Summary

MYC is crucial in aggressive B-cell lymphomas, driving tumor growth. Therapies targeting MYC are promising, but sensitivity in MYC-overexpressing lymphomas requires further investigation.

Keywords:
High-grade B-cell lymphomaMYCMYC therapiesdouble expressor lymphoma

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K

Related Experiment Videos

Last Updated: Jul 23, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The MYC oncogene is a key driver in tumorigenesis, regulating cell proliferation, growth, and survival.
  • MYC overexpression is strongly implicated in lymphomagenesis, particularly in aggressive B-cell lymphomas like high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL).
  • These MYC-addicted lymphomas are theoretically sensitive to MYC withdrawal, making MYC-targeting therapies a significant area of research.

Purpose of the Study:

  • To review current therapeutic strategies targeting the MYC oncogene in aggressive B-cell lymphomas.
  • To evaluate the predictive value of high MYC levels for sensitivity to MYC-targeting therapies.
  • To discuss novel drug development approaches for MYC-driven aggressive B-cell lymphomas, including those with MYC/BCL2 or BCL6 alterations.

Main Methods:

  • Literature review of preclinical and clinical studies on MYC-targeting therapies in aggressive B-cell lymphomas.
  • Analysis of the role of MYC in lymphomagenesis and therapeutic resistance mechanisms.
  • Categorization of emerging MYC-targeting drug classes and their mechanisms of action.

Main Results:

  • MYC overexpression is a hallmark of aggressive B-cell lymphomas, conferring addiction to MYC activity.
  • While MYC withdrawal is a therapeutic goal, the direct correlation between high MYC levels and sensitivity to targeted therapies is not fully established.
  • Several classes of molecules targeting MYC indirectly are under development, showing promise in preclinical models.

Conclusions:

  • Targeting MYC is a critical strategy for aggressive B-cell lymphomas, especially those with MYC/BCL2 or BCL6 translocations/overexpression.
  • Further research is needed to clarify sensitivity predictors and optimize therapeutic approaches.
  • Development of novel MYC inhibitors or indirect targeting strategies holds significant therapeutic potential.